Luciano J Costa, Professor at University of Alabama at Birmingham, shared a post on X:
“Among 25 multiple myeloma phase 1 trials posted in CT.gov in last 6 months, only 5 have US sites. Most innovation is from China. I just learned of two very promising approaches/drugs that completely abandoned US development. Cost of our red tape, FDA instability, moving goalposts. Successful drugs will be back 4 Ph3 , so long we remain the richest market. Our patients are being excluded from innovation, our population not represented in the studies, defeating the FDA’s own intent… frustrating.